OptimizeRx Gestione
Gestione criteri di controllo 2/4
OptimizeRx's CEO is Will Febbo, appointed in Feb 2016, has a tenure of 8.75 years. total yearly compensation is $2.79M, comprised of 16.1% salary and 83.9% bonuses, including company stock and options. directly owns 2.76% of the company’s shares, worth $2.61M. The average tenure of the management team and the board of directors is 3.5 years and 6.7 years respectively.
Informazioni chiave
Will Febbo
Amministratore delegato
US$2.8m
Compenso totale
| Percentuale dello stipendio del CEO | 16.1% |
| Mandato del CEO | 8.8yrs |
| Proprietà del CEO | 2.8% |
| Durata media del management | 3.5yrs |
| Durata media del Consiglio di amministrazione | 6.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt
Jul 30
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors
Jan 09Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)
Aug 24OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely
Aug 16Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?
May 31OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio
Oct 12Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?
Sep 23OptimizeRx extends reach with Cooler Screens Partnership
Jul 26OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability
Jun 27The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business
Nov 16Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All
Aug 13A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)
Jul 15Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation
Jun 24Investors Will Want OptimizeRx's (NASDAQ:OPRX) Growth In ROCE To Persist
May 10Estimating The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)
Mar 29Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$18m |
| Mar 31 2024 | n/a | n/a | -US$18m |
| Dec 31 2023 | US$3m | US$450k | -US$18m |
| Sep 30 2023 | n/a | n/a | -US$14m |
| Jun 30 2023 | n/a | n/a | -US$14m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$694k | US$450k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$10m |
| Jun 30 2022 | n/a | n/a | -US$7m |
| Mar 31 2022 | n/a | n/a | -US$3m |
| Dec 31 2021 | US$15m | US$410k | US$378k |
| Sep 30 2021 | n/a | n/a | US$1m |
| Jun 30 2021 | n/a | n/a | US$789k |
| Mar 31 2021 | n/a | n/a | -US$641k |
| Dec 31 2020 | US$1m | US$350k | -US$2m |
| Sep 30 2020 | n/a | n/a | -US$6m |
| Jun 30 2020 | n/a | n/a | -US$7m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$834k | US$300k | -US$3m |
| Sep 30 2019 | n/a | n/a | -US$1m |
| Jun 30 2019 | n/a | n/a | US$548k |
| Mar 31 2019 | n/a | n/a | US$422k |
| Dec 31 2018 | US$923k | US$275k | US$226k |
| Sep 30 2018 | n/a | n/a | US$99k |
| Jun 30 2018 | n/a | n/a | -US$769k |
| Mar 31 2018 | n/a | n/a | -US$1m |
| Dec 31 2017 | US$422k | US$250k | -US$2m |
Compensazione vs Mercato: Will's total compensation ($USD2.79M) is above average for companies of similar size in the US market ($USD655.65K).
Compensazione vs guadagni: Will's compensation has increased whilst the company is unprofitable.
AMMINISTRATORE DELEGATO
Will Febbo (55 yo)
8.8yrs
Mandato
US$2,789,528
Compensazione
Mr. William J. Febbo, also known as Will, is a Director at LifeMD, Inc. since June 2023. He served as an Independent Director at Augmedix, Inc. since March 28, 2022 until October 02, 2024. He served as an...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 8.8yrs | US$2.79m | 2.76% $ 2.6m | |
| President | 1.8yrs | US$970.36k | 0.42% $ 395.9k | |
| CFO & COO | 3.1yrs | US$929.73k | 0.14% $ 135.4k | |
| Senior Vice President of Corporate Finance | 3.2yrs | Nessun dato | Nessun dato | |
| General Counsel & Chief Compliance Officer | 3.8yrs | US$2.51m | 0.10% $ 97.5k | |
| Media Relations Manager | no data | Nessun dato | Nessun dato | |
| Human Resources Manager | 4.9yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Pharma | 4.7yrs | US$511.63k | Nessun dato | |
| Chief Product Officer | 2.1yrs | Nessun dato | 0.034% $ 31.9k | |
| Chief Commercial Officer | 1.1yrs | Nessun dato | 0.10% $ 95.4k | |
| Chief Revenue Officer | no data | Nessun dato | Nessun dato | |
| Controller | 6.1yrs | Nessun dato | Nessun dato |
3.5yrs
Durata media
56.5yo
Età media
Gestione esperta: OPRX's management team is considered experienced (3.5 years average tenure).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 8.5yrs | US$2.79m | 2.76% $ 2.6m | |
| Independent Director | 6.7yrs | US$215.01k | 0.18% $ 165.7k | |
| Independent Director | less than a year | Nessun dato | Nessun dato | |
| Independent Director | 4.3yrs | US$195.01k | 0.19% $ 175.3k | |
| Independent Chairperson of the Board | 9.2yrs | US$208.01k | 0.27% $ 254.9k | |
| Head of Medical Advisory Board | 6.7yrs | US$112.91k | Nessun dato | |
| Independent Director | 7.8yrs | US$204.01k | 0.30% $ 282.0k |
6.7yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: OPRX's board of directors are considered experienced (6.7 years average tenure).